Dasatinib monohydrate

CAS: 863127-77-9

Ref. TM-T1448L

Produktinformation

• Name: Dasatinib monohydrate
• Synonyme: BMS-354825 Monohydrate, 2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-N-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide hydrate (1:1), 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-, hydrate (1:1), 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-, monohydrate, Bms 35482503, Dasatinib hydrate, N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide monohydrate
• CAS: 863127-77-9

Beschreibung

Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib monohydrate binds to and inhibits the growth-promoting activities of these kinases. Apparently, because of its less stringent binding affinity for the BCR-ABL kinase, Dasatinib monohydrate has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations.

• Marke: Targetmol

Chemische Eigenschaften

• Molekulargewicht: 506.03
• Formel: C₂₂H₂₈ClN₇O₃S
• Reinheit: 100%
• Farbe/Form: Solid